PMC9083951_01
Clonal evolution of a t-CMML to AML, and during VEN/AZA combination treatment.
mjhid-14-1-e2022041f1.jpg
PMC9083951_01_mjhid-14-1-e2022041f1.jpg
f1-mjhid-14-1-e2022041
Targeted Next Generation Sequencing (t-NGS) was performed on DNA samples extracted from BM mononuclear cells (MNC) at t-CMML diagnosis, at the time of AML progression, and during treatment (at 6 and 12 months) (Figure 1). Finally, after 12 treatment cycles, most gene mutations became undetectable, with the ZRSR2 mutation burden decreasing to 1.1% (Figure 1).